GlassScriptPhysician profile
Alice E Hopple
NPI 1245252535
$10,795.49
in general payments reported to CMS, 2019-2025
32 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,277 · 2022: $2,364 · 2023: $1,953 · 2024: $2,269 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,155.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,361.58 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,126.79 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,080.83 | 2021-2025 | Lifevest |
| Amgen INC. | $1,050.08 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $903.33 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $698.04 | 2021-2025 | |
| Boston Scientific Corporation | $669.46 | 2022-2024 | Rotablator Rotational Atherectomy System Console Kit, Emblem Mri S-Icd, Ingevity Mri |
| Astrazeneca Pharmaceuticals LP | $624.02 | 2021-2025 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $516.57 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $335.08 | 2021-2023 | Xarelto |
| Daiichi Sankyo INC. | $218.36 | 2021-2023 | Injectafer |
| Novo Nordisk INC | $175.93 | 2021-2025 | Ozempic |
| Heartflow, INC. | $124.38 | 2023-2024 | Ffrct |
| G Medical Diagnostic Services, INC. | $117.95 | 2022-2023 | Cardiac Monitoring Suite |
| Cardiovascular Systems INC. | $110.02 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $88.55 | 2022-2025 | |
| Scpharmaceuticals INC. | $76.85 | 2025 | |
| Esperion Therapeutics, INC. | $76.70 | 2021-2025 | Nexletol |
| Philips North America LLC | $75.90 | 2023 | (9520) Igt Devices Undivided |
| Lilly USA, LLC | $50.19 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $44.64 | 2021 | |
| Baxter Healthcare | $35.09 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $34.14 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.46 | 2025 | |
| Biotronik INC. | $30.74 | 2022-2023 | Biomonitor |
| Vifor Pharma, INC. | $23.94 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.84 | 2025 | Uptravi |
| Lundbeck LLC | $22.40 | 2021 | |
| Abbott Laboratories | $18.43 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.93 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.27 | 2022 | |
| Abiomed | $15.00 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Hopple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.